NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Didn’t LP talk about work and progress towards a closed system manufacturing technology that reduced needs for clean rooms and automates the Dcvax production very significantly, thus reducing production costs and quality?

Anyone remember this?

ASCO 2018 Presentation for DCVax-L - Sunday, June 3, 2018

Linda Powers:

I want to just reiterate what I said at the beginning. As a company, we fully endorse, and it is our goal, for this technology to be widely available to patients. We don’t want this to be a treatment of last resort. We want this to be a frontline treatment. We’ve worked long and hard to make it practical. There’s only one manufacturing process per patient. We manufacture the whole set of doses for multi-year treatment in one batch. Then we freeze those doses, and we’ve validated the frozen shelf-life for years. So then it’s just an off-the-shelf product out of the freezer, although it’s fully personalized for that patient. So we’ve worked for years and years to try and make this a very practical product to be widely available.

Right now, it’s made by hand. That is a very obviously, expensive process. It’s the same thing that the T cell people are dealing with. And there will be steps in the future, whether it’s economies of scale, whether it’s closing the system and having to have clean rooms with people in space suits making this by hand, which is what it is today,
or full end-to-end automation. So there’s a lot of steps to be done in the future. I would say to anyone who can help us, help us provide funding, provide technical support, help spread the word, help us. We want to get this to everyone. Thank you.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142168678